Absci Corporation reported second quarter 2026 financial results and announced positive interim Phase 1 data from its HEADLINE trial of ABS-201, an anti-PRLR antibody for pattern hair loss. The company completed a $100 million underwritten offering, which included a $40 million strategic equity investment from Eli Lilly & Company. Cash, cash equivalents, and marketable securities totaled $201.1 million as of June 30, 2026, sufficient to fund operations into the second half of 2028. Revenue was $0.3 million, while net loss was $33.2 million for the quarter. The company anticipates reporting interim proof-of-concept data for ABS-201 in pattern hair loss in the second half of 2026 and full proof-of-concept data in early 2027. Absci is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI.

Absci Corporation entered into an underwriting agreement on June 24, 2026, to issue and sell 13,495,277 shares of common stock at $7.41 per share. The company expects to net approximately $93.5 million to fund the advancement of its AI-designed anti-PRLR antibody product candidate, ABS-201, for androgenetic alopecia and endometriosis, and for general corporate purposes. Absci Corp is a biotechnology company focused on developing AI-designed antibody products.

Absci Corporation announced interim Phase 1 data from its HEADLINE™ trial of ABS-201 on June 24, 2026. The company released these clinical results via a press release incorporated as Exhibit 99.1. Absci Corporation is a biotechnology company focused on drug discovery.